Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM—a prospective, randomized, single-centre, open-label study

OBJECTIVES: Severe COVID-19 is associated with an imbalanced immune response. We hypothesized that patients with enhanced inflammation, as demonstrated by increased levels of certain inflammatory biomarkers, would benefit from interleukin-6 blockage. METHODS: Patients hospitalized with COVID-19, hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Broman, Niklas, Feuth, Thijs, Vuorinen, Tytti, Valtonen, Mika, Hohenthal, Ulla, Löyttyniemi, Eliisa, Hirvioja, Tiina, Jalava-Karvinen, Päivi, Marttila, Harri, Nordberg, Marika, Oksi, Jarmo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897958/
https://www.ncbi.nlm.nih.gov/pubmed/35259529
http://dx.doi.org/10.1016/j.cmi.2022.02.027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897958/
https://www.ncbi.nlm.nih.gov/pubmed/35259529
http://dx.doi.org/10.1016/j.cmi.2022.02.027

Ejemplares similares